PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “UROLOGIC DISEASES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 199 records · Page 11Linked to original sources
PubMed2000

[Analysis of serum soluble interferon alpha/beta receptor levels in patients with urological diseases].

PURPOSE: In order to define the clinical significance of serum soluble Interferon alpha/beta receptor (sIFN alpha/beta R) levels, we determined sIFN alpha/beta R concentrations in serum of patients with urological benign and malignant diseases. MATERIALS AND METHODS: Serum sIFN alpha/beta R levels were measured in normal control (n = 22), patients with benign diseases (n = 50) included urolithiasis (n = 16), prostatic hypertrophy (n = 13), and malignant diseases included bladder cancer (n = 49), renal cell carcinoma (n = 30) and prostate cancer (n = 36) by the enzyme linked immunosolbent assay (ELISA) using monoclonal and polyclonal antibodies. The levels of serum sIFN alpha/beta R was correlated with the results of other hematoserological examinations, and clinical or pathological characters of each urological malignancies. RESULTS: The serum sIFN alpha/beta R levels (pg/ml) of patients with urolithiasis (2,370.6 +/- 640.6, p = 0.0002), benign prostatic hypertrophy (2,121.1 +/- 550.6, p = 0.0103), bladder cancer (2,512.3 +/- 1,012.3, p = 0.0006), renal cell carcinoma (2,686.4 +/- 1,510.9, p = 0.0046), prostate cancer (3,188.7 +/- 1,788.0, p = 0.0003) showed significantly higher values than those of controls (1,709.5 +/- 346.7). Moreover, we found statistically significant correlations among serum creatinine (Cr) levels and sIFN alpha/beta R levels. However, there were no correlations between the sIFN alpha/beta R levels and clinical stage, or histological grade in the patients with bladder cancer or prostate cancer, whenever the levels of sIFN alpha/beta R were corrected by serum Cr levels. On the other hand, high level of corrected serum sIFN alpha/beta R was observed in patients with high stage or high grade renal cell carcinoma, but not significant statistically. CONCLUSIONS: Elevated serum sIFN alpha/beta R was observed in patients with urological disease. Further examinations should be necessary to determine the clinical usefulness of serum sIFN alpha/beta R.

Adolescent↗